Company news
Soligenix, Inc. (NASDAQ:SNGX) news
Soligenix, Inc. news releases on 6ix. Latest, May 9, 2023: Soligenix Announces Closing of $8.5 Million Public Offering
Press releases — page 3
Soligenix Announces Closing of $8.5 Million Public Offering
May 8, 2023
Soligenix Announces Pricing of $8.5 Million Public Offering
May 4, 2023
Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
May 3, 2023
Soligenix Announces Appointment of Timothy R. Coté, M.D. to its Board of Directors
May 2, 2023
Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet's Disease
April 30, 2023
Soligenix Submits Type A Meeting Request to U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
April 23, 2023
Soligenix Provides Regulatory Update on HyBryte™
April 13, 2023
Soligenix Receives USAN Approval for "Hypericin Sodium" as Nonproprietary Name for Novel Active Ingredient in HyBryte™ and SGX302
April 4, 2023
Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
April 2, 2023
Soligenix Announces Recent Accomplishments And Year-End 2022 Financial Results
March 30, 2023
Soligenix Announces Distribution of Series D Preferred Stock to Holders of its Common Stock
December 22, 2022
Soligenix Announces Publication Demonstrating Positive Correlates of Protection with RiVax® in Non-Human Primate Survival after Ricin Challenge
December 19, 2022
Soligenix Initiates Phase 2 Clinical Trial of SGX302 (synthetic hypericin) for the Treatment of Mild-to-Moderate Psoriasis
December 18, 2022
Soligenix Announces Submission of New Drug Application to the FDA for HyBryte™ in the Treatment of Cutaneous T-cell Lymphoma
December 14, 2022
Soligenix Announces Recent Accomplishments And Third Quarter 2022 Financial Results
November 9, 2022
Soligenix Announces Formation of Psoriasis Medical Advisory Board
October 24, 2022
Soligenix Announces Adjournment of Annual Meeting and Information for Reconvened Meeting
October 19, 2022
Soligenix Announces Partial Adjournment of Annual Meeting and Information for Reconvened Annual Meeting
September 22, 2022
Soligenix Announces Recent Accomplishments And Second Quarter 2022 Financial Results
August 11, 2022
Soligenix Receives Agreement from FDA on Initial Pediatric Study Plan for HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
July 26, 2022
Soligenix's HyBryte(TM) Treatment Now Within Reach for Rare Cancer Patients
July 25, 2022
Soligenix Announces Strategic Partnership with SERB Pharmaceuticals to Supply its Novel Ricin Antigen
July 24, 2022
Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in the Treatment of Psoriasis
June 27, 2022
Soligenix Announces Successful Protection using a Bivalent Thermostabilized Filovirus Vaccine
June 22, 2022
Soligenix Receives US Patent Allowance for its Thermostabilized Vaccine Platform
May 22, 2022
Soligenix Announces Recent Accomplishments And First Quarter 2022 Financial Results
May 12, 2022
Soligenix Receives $1.4M in Non-Dilutive Government Funding
April 18, 2022
Soligenix Announces Recent Accomplishments And Year-End 2021 Financial Results
March 28, 2022
Soligenix COVID-19 Vaccine, CiVax™, Boosts Neutralizing Activity against SARS-CoV-2, including Delta and Omicron
March 16, 2022
Soligenix Corporate Update Includes NDA Plans for HyBryte(TM)
January 11, 2022
Soligenix Announces Recent Accomplishments And Third Quarter 2021 Financial Results
November 11, 2021
Soligenix Granted Pediatric Investigational Plan Waiver for HyBryte™ in CTCL in the United Kingdom
November 7, 2021
Soligenix Announces Publication Demonstrating Enduring Protection of its Thermostable RiVax® Vaccine
November 3, 2021
Soligenix Announces Accelerated Publication Demonstrating Efficacy and Broad Neutralizing Activity of its COVID-19 Vaccine in Non-Human Primates
September 27, 2021
Soligenix to Advance Synthetic Hypericin Development in Psoriasis
September 15, 2021
FDA Grants Soligenix Orphan Drug Designation for the Treatment of T-cell Lymphoma
September 8, 2021
Soligenix Announces Publication Demonstrating Successful Formulation and Heat Stabilization of Filovirus Vaccine Platform for Ebola and Marburg Virus Diseases
August 22, 2021
Soligenix Announces Positive Preclinical Data with Multiple Heat Stable Filovirus Vaccine Candidates
August 17, 2021
Soligenix Announces Recent Accomplishments And Second Quarter 2021 Financial Results
August 12, 2021
Soligenix Receives Pediatric Investigational Plan Waiver for HyBryte™ in CTCL from the European Medicines Agency
June 9, 2021
Soligenix Receives $865,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
June 8, 2021
Soligenix Receives Japanese Patent for Improved Production of Synthetic Hypericin Composition
May 19, 2021
Soligenix Announces Recent Accomplishments And First Quarter 2021 Financial Results
May 16, 2021
Soligenix Announces Presentations at Prominent Scientific Conferences
April 12, 2021
Soligenix Receives Conditional FDA Acceptance of Proposed Brand Name HyBryte™ for SGX301 in CTCL
April 6, 2021
Soligenix Announces Recent Accomplishments And Year-End 2020 Financial Results
March 29, 2021
Soligenix to Receive $865,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
March 8, 2021
Soligenix Announces Positive Progress in the Pre-clinical Development of its COVID-19 Vaccine
March 3, 2021
Soligenix is Ready for Commercialization of SGX301 (HyBryte(TM)); FDA Has Approval Process on Fast Track
February 22, 2021
Soligenix Receives Hong Kong Patent for Therapeutic Use of Synthetic Hypericin to Treat Cutaneous T-Cell Lymphoma
January 31, 2021